Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and understanding of the disease’s pathophysiology has improved, pharmacological treatments with proven outcomes benefits in HFpEF have been elusive. Indeed, drug treatment still focuses on managing comorbidities, and first-line treatment typically consists of RAAS inhibitors, beta blockers, and diuretics. Also, unlike in heart failure patients with reduced ejection fraction (HFrEF), calcium channel blockers can be used in this subpopulation. Recently, Jardiance and Entresto secured FDA approval to treat HFpEF; these agents are already approved for HFrEF. This analysis provides insight into U.S. prescribing patterns for HFpEF.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HFpEF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFpEF patients?
- How have Entresto and Jardiance been integrated into the treatment algorithm, and what is their source of business?
- What percentage of HFpEF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one of diagnosis?
- What percentage of HFpEF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Pfizer, Merck, Novartis, GSK, AstraZeneca, Johnson & Johnson, Eli Lilly, Boehringer Ingelheim, Amgen
Key drugs: ACE inhibitors, ARBs, beta blockers, diuretics, aldosterone antagonists, nitrates, BiDil, Corlanor, Entresto
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Heart Failure - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Heart Failure - Preserved Ejection Fraction (US)
- Treatment Algorithms CDA Heart Failure with Preserved Ejection Fraction US May 2023
- Treatment Algorithms CDA HFpEF 2023 Dashboard
Anuhya V., M.Pharm., is a research associate on the Cardiovascular, Metabolic, Renal, and Hematological Disorders team at Clarivate. She conducts extensive secondary market research for a variety of CMRH indications, including pulmonary hypertension (PH), nonalcoholic steatohepatitis (NASH), heart failure (including HFrEF & HFpEF). She holds a M.Pharm. degree in general pharmacy from BITS Pilani in India and a bachelor’s degree in pharmacy from G. Pulla Reddy College of Pharmacy, which is affiliated with Osmania University, in Hyderabad, India.